0001567619-18-001208.txt : 20180815
0001567619-18-001208.hdr.sgml : 20180815
20180815172704
ACCESSION NUMBER: 0001567619-18-001208
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180813
FILED AS OF DATE: 20180815
DATE AS OF CHANGE: 20180815
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Van Naarden Jacob
CENTRAL INDEX KEY: 0001661254
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36562
FILM NUMBER: 181021819
MAIL ADDRESS:
STREET 1: C/O LOXO ONCOLOGY, INC.
STREET 2: ONE LANDMARK SQUARE, SUITE 1122
CITY: STAMFORD
STATE: CT
ZIP: 06901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Loxo Oncology, Inc.
CENTRAL INDEX KEY: 0001581720
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462996673
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06901
BUSINESS PHONE: 203-653-3880
MAIL ADDRESS:
STREET 1: 281 TRESSER BOULEVARD, 9TH FLOOR
CITY: STAMFORD
STATE: CT
ZIP: 06901
4
1
doc1.xml
FORM 4
X0306
4
2018-08-13
0
0001581720
Loxo Oncology, Inc.
LOXO
0001661254
Van Naarden Jacob
C/O LOXO ONCOLOGY, INC.
ONE LANDMARK SQUARE, SUITE 1122
STAMFORD
CT
06901
0
1
0
0
Chief Business Officer
Common Stock
2018-08-13
4
M
0
5500
3.648
A
19200
D
Common Stock
2018-08-13
4
S
0
730
157.6155
D
18470
D
Common Stock
2018-08-13
4
S
0
3070
158.6619
D
15400
D
Common Stock
2018-08-13
4
S
0
1500
159.6893
D
13900
D
Common Stock
2018-08-13
4
S
0
200
160.5950
D
13700
D
Common Stock
2018-08-14
4
M
0
4500
3.648
A
18200
D
Common Stock
2018-08-14
4
S
0
600
159.0820
D
17600
D
Common Stock
2018-08-14
4
S
0
3199
159.9070
D
14401
D
Common Stock
2018-08-14
4
S
0
701
160.6997
D
13700
D
Employee Stock Option (Right to Buy)
3.648
2018-08-13
4
M
0
5500
0
D
2024-06-18
Common Stock
5500
72769
D
Employee Stock Option (Right to Buy)
3.648
2018-08-14
4
M
0
4500
0
D
2024-06-18
Common Stock
4500
68269
D
The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
Represents the aggregate of sales effected on the same day at different prices.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.04 to $157.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.11 to $159.09 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.26 to $160.23 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.49 to $160.70 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.43 to $159.27 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.46 to $160.35 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.48 to $161.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
/s/Jennifer Burstein, by power of attorney
2018-08-15